Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

• Early results with teclistamab combined with anti-CD38 therapy
• Real-world data with teclistamab including its use after other BCMA-targeted therapies
• Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
• Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/40bjFCZ